论文部分内容阅读
目的比较替吉奥联合顺铂(SP)方案与FOLFOX4方案治疗晚期胃癌的近期效果及不良反应。方法将50例确诊的晚期胃癌患者随机分为两组。观察组25例用SP方案化疗,对照组25例用FOLFOX4方案化疗,两组患者均治疗至少3个疗程后用评价两种化疗方案的近期疗效和不良反应。结果观察组CR 2例,PR12例,SD 10例,PD 1例,总有效率为56%;对照组CR 0例,PR 11例,SD 11例,PD 3例,总有效率为44%,两组近期疗效差异无统计学意义(P>0.05)。观察组白细胞减少、恶心、呕吐、腹泻等胃肠道反应的发生率低于对照组(P<0.05)。结论 SP方案与FOLFOX4方案治疗晚期胃癌的近期疗效相当,但前者不良反应较少,患者依从性更高。
Objective To compare the short-term effects and side effects of the combination of tegaserod and cisplatin (SP) with FOLFOX4 regimen in the treatment of advanced gastric cancer. Methods Fifty patients with diagnosed advanced gastric cancer were randomly divided into two groups. In the observation group, 25 cases were treated with SP regimen, 25 cases in the control group were treated with FOLFOX4 regimen, and both groups were treated with at least 3 courses to evaluate the short-term efficacy and adverse reactions of the two regimens. Results CR 2, PR 12, SD 10 and PD 1 were observed in observation group. The total effective rate was 56% in CR 0, 11 cases in PR, 11 cases in SD and 3 cases in PD. The total effective rate was 44% No significant difference between the two groups in the short term efficacy (P> 0.05). The incidence of gastrointestinal reactions such as leukopenia, nausea, vomiting and diarrhea in observation group was lower than that in control group (P <0.05). Conclusion The SP regimen is similar to the FOLFOX4 regimen in the treatment of advanced gastric cancer, but the former has less adverse reactions and the patients have higher compliance.